Champions Oncology to Announce Third Quarter Financial Results on Wednesday, March 15, 2023

HACKENSACK, NJ / ACCESSWIRE / March 13, 2023 / Champions Oncology, Inc. (NASDAQ: CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2023, on Wednesday, March 15, 2023, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 500542. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 47846, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.




View source version on accesswire.com:
https://www.accesswire.com/743362/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Wednesday-March-15-2023

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.68
+6.26 (2.63%)
AAPL  258.27
+2.86 (1.12%)
AMD  252.03
+0.72 (0.29%)
BAC  52.17
+0.15 (0.29%)
GOOG  335.00
+1.41 (0.42%)
META  672.97
+0.61 (0.09%)
MSFT  480.58
+10.30 (2.19%)
NVDA  188.52
+2.05 (1.10%)
ORCL  174.90
-7.54 (-4.13%)
TSLA  430.90
-4.30 (-0.99%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.